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Background: Protein aggregation and the formation of intracellular inclusions are a central feature of many
neurodegenerative disorders, but precise knowledge about their pathogenic role is lacking in most instances. Here
we have characterized inclusions formed in transgenic mice carrying the P56S mutant form of VAPB that causes
various motor neuron syndromes including ALS8.
Results: Inclusions in motor neurons of VAPB-P56S transgenic mice are characterized by the presence of smooth
ER-like tubular profiles, and are immunoreactive for factors that operate in the ER associated degradation (ERAD)
pathway, including p97/VCP, Derlin-1, and the ER membrane chaperone BAP31. The presence of these inclusions
does not correlate with signs of axonal and neuronal degeneration, and axotomy leads to their gradual
disappearance, indicating that they represent reversible structures. Inhibition of the proteasome and knockdown of
the ER membrane chaperone BAP31 increased the size of mutant VAPB inclusions in primary neuron cultures, while
knockdown of TEB4, an ERAD ubiquitin-protein ligase, reduced their size. Mutant VAPB did not codistribute with
mutant forms of seipin that are associated with an autosomal dominant motor neuron disease, and accumulate in
a protective ER derived compartment termed ERPO (ER protective organelle) in neurons.
Conclusions: The data indicate that the VAPB-P56S inclusions represent a novel reversible ER quality control
compartment that is formed when the amount of mutant VAPB exceeds the capacity of the ERAD pathway and
that isolates misfolded and aggregated VAPB from the rest of the ER. The presence of this quality control
compartment reveals an additional level of flexibility of neurons to cope with misfolded protein stress in the ER.
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reproduction in any medium, provided the oraggregates or have disease or morphology specific names
(e.g. Lewy bodies, Pick bodies, neurofibrillary tangles), and
can be correlated to specific disorders [1]. Not only the
protein composition, but also the morphologies as well as
(sub) cellular and regional distributions of inclusions can
be correlated to specific disorders and subtypes of disor-
ders [1-3]. Depending on the type of disorder and inclu-
sion, inclusions may be either neuroprotective, neutral or
detrimental structures, and precise knowledge about their
characteristics is instrumental for our understanding of
neurodegenerative disorders [1,4].
A peculiar inclusion that is ultrastructurally character-
ized by the presence of ER-derived membranous profilesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ALS-like disorder designated ALS8 [5-7]. ALS8 is caused
by mutation in VAPB [8], a small tail-anchored ER mem-
brane protein that is member of a conserved VAP (VAMP/
synaptobrevin-associated proteins) family of proteins. Sev-
eral VAPB mutations have been identified, but so far only
a P56S mutation is yet known to co-segregate with
disease [8,9]. VAP proteins are characterized by an N-
terminal MSP (major sperm protein) domain, a coiled-
coil motif, and a C-terminal transmembrane region, and in
mammals consists of two genes, VAPA and VAPB [10,11].
The MSP domain (named after C. elegans MSP) contains a
binding site for the FFAT (diphenylalanine [FF] in an acidic
tract) that are present in a variety of proteins [12,13]. In
addition, the MSP domain may function as a secreted lig-
and after cleavage from the transmembrane domain [7].
VAPs have been implicated in multiple function includ-
ing non-vesicular transfer of lipids and membrane traf-
ficking, ER-organelle and ER-cytoskeleton interaction
and homeostatic and signaling functions at the neuro-
muscular synapse [10,14-16].
The P56S mutation causes rapid oligomerization and
aggregation of mutant VAPB, and typically accumulates
in multiple dot-like inclusions in transfected cells and ani-
mal models, including transgenic mice [6,8,17,18]. Several
mechanisms by which mutant VAPB causes ALS have
been proposed, including a dominant negative mode of
action by recruiting wild-type VAPB and VAPA or other
factors into aggregates, a gained toxic activity, or partial
loss of function [5,6,15,19-21]. The aim of this study was
to further characterize mutant VAPB inclusions in vivo in
neurons of P56S-mutant VAPB transgenic mice. The data
indicate that mutant VAPB inclusions that occur in motor
neurons of these mice represent a specialized ER associ-
ated protein quality control compartment that isolates
misfolded and aggregated VAPB targeted for degrad-
ation from the rest of the ER. The presence of this quality
control compartment in addition to the ER associated
degradation machinery may explain the late onset of mu-
tant VAPB-induced disease in man.
Methods
Transgenic mice
Animals were housed and handled in accordance with the
“Principles of laboratory animal care” (NIH publication
No. 86–23) and the guidelines approved by the Erasmus
University animal care committee.
Transgenic VAPB mice were generated using the cDNAs
of wild-type or P56S-mutant human VAPB cloned into
the Thy1.2-expression module (Figure 1A). The VAPB-
constructs also contained an HA-tag to enable easy
visualization of transgenic VAPB by immunocytochem-
ical approaches. Experiments in transfected cells have
shown that the HA-tag does not alter the biochemicalcharacteristics of wild-type and mutant VAPB [6]. Pro-
nuclear injections yielded multiple founders carrying wild-
type hVAPB or hVAPB-P56S. Data in this study were
obtained from F1 - F10 offspring of 3 hVAPB-WT (VW1,
VW2, VW3) and 4 hVAPB-P56S (VM1, VM2, VM3, VM5)
founders. Lines were maintained in FVB background by
crossing hemizygote males with non-transgenic females.
A selected group of different transgenic lines was allowed
to age for 2 years (Additional file 1: Table S1). These mice
were weighed and inspected for signs of muscle weakness
once a week, using a set of simple tests: i.e. the mice were
examined for their ability to extend their hindlimbs when
suspended in the air by their tail, and their ability to hang
upside down on a grid for 60 s [22]. In addition, at specific
ages animals were subjected to an accelerating rotarod test
as described [23]. The mice were killed when they devel-
oped motor problems or when they reached 2 years of age
(Additional file: 1 Table S1). A subset of mice was excluded
from the study because of non-motor related discomfort
(e.g. eye infections or tumors; see Additional file 1:
Table S1). Selected mice were analyzed for neuromuscular
denervation and pathological abnormalities in the spinal
cord (e.g. motor neuron loss, gliosis).
Axotomy of the sciatic nerve
Six weeks old hemizygote hVAPB-P56S mice from the
VM1 line and their non-transgenic littermates were anes-
thetized. The left sciatic nerve was exposed, bound with
suture and cut at mid-thigh level. After various intervals
mice were perfused transcardially with 4% paraformalde-
hyde and processed for immunocytochemistry.
Antibodies
Primary antibodies reported in this study are: mouse anti-
actin (Millipore); mouse anti-αB-crystallin (Stressgen Bio-
technologies); rabbit anti-ATF3 (Santa Cruz Biotechnology);
rabbit anti-BAP31 rabbit (gift from M. Tagaya; Tokyo Uni-
versity of Pharmacy and Life Sciences [24]); rabbit anti-BiP/
GRP78 (Stressgen Biotechnologies); rabbit anti-calreticulin
(Affinity BioReagents); mouse anti-CD8 (SantaCruz); goat-
anti-choline acetyltransferase (ChAT, Millipore); rabbit-
anti-CGRP (Calbiochem); rabbit anti-Derlin-1 (D4443,
Sigma-Aldrich); rabbit anti-GFAP (DAKO); mouse-anti
GM130 (BD Biosciences); mouse anti-HA (Covance);
rat anti-HA (Roche); rabbit anti-HA (Santa Cruz Bio-
technology); rabbit anti-Iba1 (WAKO Chemicals); rat
anti-Mac2 (Cedarlane); rabbit anti KDEL (Stressgen
Biotechnologies); rabbit anti-myc (Cell Signaling Tech-
nology); mouse anti-myc (Santa Cruz Biotechnology);
mouse anti-NeuN (MAB377, Millipore); chicken anti-
neurofilament M (Millipore), rabbit anti-NIR2 (Santa
Cruz Biotechnology); rabbit anti-ORP9 (gift from Neale
Ridgway, Dalhousie University, Canada); rabbit anti-ORP2,
rabbit anti-ORP3, rabbit anti-ORP6 (gifts from Vesa
Figure 1 Generation of VAPB-WT and VAPB-P56S transgenic mice. A) To generate VAPB transgenic mice the cDNAs of wild-type or P56S-mutant
human VAPB coupled to HA were cloned into the Thy1.2-expression casette. B-E) Western blots showing relative VAPB transgene expression levels in
tissues of Thy1.2-hVAPB-WT (VW2, VW3) and Thy1.2-hVAPB-P56S (VM1, VM2, VM3) mice. Transgenic VAPB is detected with anti-HA antibody that
specifically detects the transgene (B) or anti-VAPB antibody that interacts with both endogenous VAPB and transgenic VAPB running in a higher
molecular weight band because of the HA-tag (B, D, E). Each lane is loaded with 2.5 μl S1 fraction derived from 250 μg tissue. B, C) Representative
results (B) and quantification (C) of Western blot of spinal cord homogenates showing relatively high transgene expression levels in wild-type VAPB
expressing lines (VW2 and VW3), and moderate transgene expression in mutant VAPB lines (VM1, VM2). Values in C are expressed as the ratio of the
signals of endogenous and transgenic VAPB and represent means ± SE (n > 3). Spinal cords from VM2 mice show about half the level of transgene
expression compared to VM1 spinal cord (Student t-test). D) Western blot of homogenates from different tissues from VM1 and VM3 mice showing
that the transgene is specifically expressed in nervous system. E) Western blot of sciatic nerve homogenate of wild-type (line VW3) and mutant (line
VM1) transgenic mice showing a high level of transgenic VAPB in wild-type VAPB sciatic nerve, and no transgenic VAPB in mutant VAPB sciatic nerve.
F) Anti-HA immunohistochemistry showing widespread transgene expression in the brain of wild-type and mutant VAPB transgenic mice.
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human anti-ribosomal protein P0 (Immunovision); Rabbit
anti-phosphoS6 (Cell Signaling Technology), mouse
anti-ubiquitin (FK2; 1:300; Biomol); rabbit anti-VAPB
[6]; guinea pig anti-VAChT (Millipore); mouse anti-VCP
(Ma3-004; Thermo Scientific).
Secondary antibodies: For avidin-biotin-peroxidase im-
munocytochemistry biotinylated secondary antibodies from
Vector Laboratories diluted 1:200 were used. FITC-, Cy3-,
and Cy5-conjugated secondary antibodies raised in donkey
(Jackson Immunoresearch, USA), Alexa488, 568 or 633
conjugated antibodies raised in goat were used for im-
munofluorescence. For Western blots, HRP-conjugated
goat-anti mouse or goat-anti rabbit IgG were used at
1:5000 (DAKO, 1:5000).
Western blotting
Tissue samples were homogenized in ten volumes of
PBS containing 0.5% Nonidet P-40 and 1× proteaseinhibitor cocktail (Complete, Roche), sonicated and cen-
trifuged at 800 g for 15 min at 4°C to obtain the S1-
supernatant. For the preparation of detergent-insoluble
extracts, S1 supernatants were centrifuged at 15000 g for
20 min. After the collection of supernatants (S2), pellets
(P2) were thoroughly washed five times with PBS-0.5%
Nonidet P-40 and then resuspended in sample buffer for
SDS–PAGE electrophoresis and western blotting. Protein
concentrations in samoles were determined using the
BCA method (Pierce, Rockford, IL).Samples containing
5–50 mg protein were electrophoresed on SDS–PAGE
gels and blotted on PVDF membranes (Millipore). The
membranes were blocked with 5% non-fat dry milk
(Bio-Rad) in PBS with 0.05% Tween20 (PBST), incu-
bated in primary antibody, diluted in PBST with 1% dry
milk followed by incubation in secondary antibody.
Blots were exposed to film after incubation in chemilu-
minescence’s reagent (ECL, Amersham), and films were
analyzed with Metamorph software.
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Levels of unfolded protein stress responsive mRNAs were
analyzed by real time quantitative reverse transcription
PCR (qRT-PCR) using the Roche LightCycler 480 and the
Roche universal probe library as described [25]. RNA was
isolated from cortex samples using Trizol reagent and used
for cDNA synthesis. Primers for the qRT-PCR assay were:
BiP FW: gccaactgtaacaatcaaggtct/RV: tgacttcaatctggggaactc
(probe #15) and Chop FW: ccaccacacctgaaagcag/RV: tcctca
taccaggcttcca (probe #33). Values are normalized to eEF2α
mRNA FW: acacgtagattccggcaagt/RV: aggagccctttcccatctc
(probe #31) for individual animals [25].Primary neuron cultures and transfection
Primary hippocampal cultures were prepared from embry-
onic day 18 (E18) rat brains [26]. Cells were plated on cov-
erslips coated with poly-L- lysine (30 μg/ml) and laminin
(2 μg/ml) at a density of 75,000/well. Hippocampal cultures
were grown in Neurobasal medium (NB) supplemented
with B27, 0.5 mM glutamine, 12.5 μM glutamate and
penicillin/streptomycin. Hippocampal neurons were trans-
fected using Lipofectamine 2000 (Invitrogen). The follow-
ing mammalian expression plasmids have been described
previously: HA- and myc-tagged VAPB-wt and VAPB-
P56S constructs [6]; myc-tagged seipin-wt, seipin-N88S
and seipin-S90L constructs [27]; and BAP31-mRFP con-
struct [24]. ΔTM-VAPB-P56S-GFP was generated by a
PCR-based strategy using HA-VAPB-P56S construct as
a template and subcloned into a GFP-tagged pβactin ex-
pression vector. HA-VAPB-P56S-CD8TM was made by
removing the transmembrane domain of VAPB-P56S
and adding the transmembrane domain of CD8 with a
PCR-based strategy using HA-VAPB-P56S and GFP-CD8
[28] as a template and subcloned into a pβactin expression
vector. BAP31 (5’-gagaatgatcagctaaaga-3’) and TEB4 (5’-
ttaagagcctcttgcctca-3’) shRNA construct sequences were
designed based on previously published sequences [29,30].
The complementary oligonucleotides were annealed and
inserted into a pSuper vector [31]. DNA (3.6 μg /well)
was mixed with 3 μl of Lipofectamine 2000 in 200 μl of
medium, incubated for 30 min, and then added to the
neurons in NB at 37°C in 5% CO2 for 45 min. Next,
neurons were washed with NB and transferred in the
original medium at 37°C in 5% CO2. 2–4 days after trans-
fection, neurons were fixed with 4% paraformaldehyde/4%
sucrose in PBS, washed three times in PBS for 10 min and
incubated with the indicated primary antibodies in GDB
buffer (0.2% BSA, 0.8 M NaCl, 0.5% Triton X-100, 30 mM
phosphate buffer, pH 7.4) overnight at 4°C. Following
incubation with secondary antibody neurons were mounted
using Vectashield mounting medium (Vector laboratories).
Images for co-localization measurements were acquired
using a Nikon microscope equipped with a 100x oilobjectives. Confocal images were acquired using a LSM510
confocal microscope (Zeiss) with 40x or 63x oil objectives.Immunohistochemical and histopathological procedures
For immunocytochemistry and immunofluorescence mice
were anaesthetized with pentobarbital and perfused trans-
cardially with 4% paraformaldehyde. The lumbar and
cervical spinal cord were carefully dissected out and
post-fixed overnight in 4% paraformaldehyde. Routinely,
spinal cord tissue was embedded in gelatin blocks,
sectioned at 40 μm with a freezing microtome and sec-
tions were processed, free floating, employing a standard
avidin-biotin-immunoperoxidase complex method (ABC,
Vector Laboratories, USA) with diaminobenzidine (0.05%)
as the chromogen, or single, double and triple-labelling
immunofluorescence [22]. Immunoperoxidase-stained sec-
tions were analyzed and photographed using a Leica
DM-RB microscope and a Leica DC300 digital camera.
Sections stained for immunofluorescence were mounted
on coverslips, placed on glass slides with Vectashield
mounting medium, and were examined with Zeiss LSM
510 and LSM 700 confocal laser scanning microscopes.
For analysis of neuromuscular denervation medial gas-
trocnemius muscle from 4% paraformaldehyde fixed mice
were dissected, embedded into gelatin blocks and sectioned
at 80 μm with a freezing microtome [22]. Sections were
immunolabeled, free floating, for guinea pig anti-VAChT
and chicken-anti-NFM followed by Cy3 anti-goat and
Cy5 anti-chicken or anti-rabbit secondary antibody, and
motor endplates were labeled with FITC-bungarotoxin
(1:500, Molecular Probes). For quantitative analyses, muscle
sections were examined under a Leica DM-RB fluorescence
microscope, end-plates being scored as ‘innervated’ in case
of complete overlap between bungarotoxin and VAChT la-
beling, ‘partially denervated’ in case of partial overlap, and
‘denervated’ in case of the absence of VAChT labeling at
the end-plate.Quantitative analysis of immunofluorescence images
Fluorescent intensities and inclusion sizes were deter-
mined using Metamorph image analysis software. Images
were collected using Zeiss LSM 510 confocal laser scan-
ning microscope with 63x Plan apo oil immersion ob-
jective. Analyses of inclusions in cultured neurons were
performed on maximal projections of confocal stacks. For
analysis of FK2-labeled motor neurons stacks of 1 μm
thick sections were collected from the first 4 μm facing
the coverslip, and the optical section 2 μm below the sur-
face of the section was used for density measurements.
Material from non-transgenic and transgenic mice always
was imbedded in a single gelatin block to minimalize
variability in staining intensity resulting from the sec-
tioning and immunostaining procedure [22]. Per mouse,
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(yielding 4–12 cells/sections) were measured.
Analyses of sciatic nerves
Sciatic nerves were carefully dissected from perfused mice,
post-fixed in 4% paraformaldehyde with 1% glutaralde-
hyde, extensively rinsed in 0.1 M PB, post-fixed in 1%
osmium, dehydrated, embedded in Durcupan, sectioned
transversely at 0.5 μm with an Ultratome, and stained
with toluidine blue.
Transmission electron microscopy
For electron microscopy mice were perfused transcardially
with 4% paraformaldehyde with 0.2% (post-embedding
immunogold electron microscopy) or 1% (standard trans-
mission electron microscopy) glutaraldehyde. Specimens
were sectioned with a Vibratome and further processed
using standard methods as described before [22,32]. For
standard transmission electron microscopy Vibratome sec-
tion (60–100 μm) were post-fixed in 1% osmium, dehydrated
and embedded in Durcupan. Ultrathin sections (50–70 nm)
were contrasted with uranyl acetate and lead citrate, and
analyzed in a Phillips CM100 electron microscope at 60
or 80 kV.
Post-embedding immunogold labeling was performed on
50–70 nm thick thin sections from 4% paraformaldefyde
and 0.2% glutaraldehyde fixed brain and spinal cord sec-
tions as described before [22] using the rat-anti-HA anti-
body at 1:100.
For electron microscopic analysis of VAPB-P56S inclu-
sions in HeLa cells, cells were transfected with Myc-
hVAPB-P56S and the Addgene plasmid 40307 to enable
selection of transfected cells under the electron micro-
scope [33]. 24 h after transfection cells were fixed with 2%
paraformaldehyde and 2.5% glutaraldehyde in cacodylate
buffer, stained for DAB [33], post-fixed with 1% OsO4
(EMS) and 1.5% K4[Fe(CN)6] in cacodylate buffer (90 min
on ice), followed by 1% low molecular weight tannic acid
(30 min at RT) and with 1% OsO4 in distilled water
(30 min on ice) as described [34], embedded in epon,
sectioned at 50 nm, and contrasted with uranyl acetate [6].
Statistical analyses
Statistical analyzes were performed with MS Excel or
Graphpad Prism software (San Diego, USA). Means from
different age groups, and different transgenic mouse lines
were compared using Student’s t-test, or one-way ANOVA
and Tukey’s post-test.
Results
Mutant VAPB inclusions are positive for luminal ER
proteins and are surrounded by ribosome-rich areas
To examine mutant VAPB inclusions in neurons in vivo
we generated transgenic mice carrying a construct ofhuman VAPB cDNA with or without the P56S mutation
cloned into the Thy1.2 expression cassette (Figure 1A)
that drives transgene expression in neurons throughout
the CNS, including spinal motor neurons [22,35]. The
transgenes incorporated an HA-tag at the N-terminus
to enable the efficient localization of transgenic protein
at the light and ultrastructural level [36]. Four lines of
hVAPB-P56S (VM1, VM2, VM3, VM5) and 3 lines of wild-
type (wt)-hVAPB (VW1, VW2, VW3) transgenic mice were
obtained (Figure 1; Additional file 1: Figure S1). Consistent
with previous studies with transfected cells [6,8] and trans-
genic mice [17,18], hVAPB-P56S expressing trangenic mice
developed VAPB inclusions in motor neurons as well as
other populations of neurons, including spinal interneu-
rons, neurons in brain stem reticular formation and the
cerebellar nuclei, and pyramidal neurons in neocortex.
Mutant VAPB inclusions consisted of small spherical and
ellipsoid structures that were intensely HA and VAPB-
immunoreactive, and were distributed throughout the cell
body and proximal dendrites (Figure 2). Significantly, the
mutant VAPB inclusions did not occur in mutant VAPB
transgenic mice from line VM2, which showed lower
transgene expression levels than the other lines (Figure 1;
Additional file 1: Figure S2). Inclusions also were absent
in wild-type VAPB transgenic mice (see below).
To determine whether the presence of inclusions was
associated with altered solubility of mutant VAPB we
performed Western blot analysis of non-ionic detergent
(Nonidet P40)-insoluble (P2) fraction of spinal cord hom-
ogenate. In accordance with reduced solubility a large pro-
portion of transgenic mutant VAPB accumulated in the
insoluble fraction (Additional file 1: Figure S2). Endogenous
murine VAPB was not detectable in this fraction, suggesting
that it does not coaggregate with transgenic mutant VAPB
(Additional file 1: Figure S2).
To characterize the mutant VAPB inclusions we first
double stained for HA or VAPB and a variety of cellular
markers. Double labeling with antibodies against calreticulin
(a luminal ER sugar-binding protein) and KDEL (a C-
terminal tetrapeptide motif shared by several ER chaper-
ones), showed that the mutant VAPB inclusions were
immunoreactive for these ER markers (Figure 2C-F).
However calreticulin and KDEL staining was not enriched
in the inclusions; the same staining intensity is observed
in the inclusions as compared to the surrounding area.
Accordingly, the calreticulin and KDEL staining in motor
neurons with inclusions was indistinguishable from that in
non-transgenic motor neurons (e.g. compare Figure 2C
and 2E with 2D’ and F’, respectively). Double labeling with
antibodies against ribosomal protein P0 and phosphory-
lated ribosomal protein S6 showed that while the inclu-
sions were immunonegative for P0 and phospho-S6, the
area around the inclusions contains a high density of ribo-
somes (Figure 2G, H). The specific association of mutant
Figure 2 VAPB Inclusions in VAPB-P56S transgenic motor neurons are immunoreactive for ER markers and surrounded by ribosomal
markers. A, B) Confocal immunofluorescence of HA (specific for transgenic VABP) and VAPB (labels endogenous and transgenic VAPB) in motor
neurons of non-transgenic (A) and mutant VAPB (line VM1; B) mice showing multiple small intensely HA and VAPB-immunoreactive inclusions in
VM1 motor neurons. Note, that VAPB-immunoreactivity in the rest of the cell body is the same as in non-transgenic mice. C-F) Confocal
immunofluorescence of spinal motor neurons double-labeled with either anti-HA; C, D) or anti-VAPB; E, F) and antibodies against ER proteins,
i.e. calreticulin (C, D) or KDEL-motif proteins (E, F); calreticulin and KDEL-immunoreactivities are diffusely distributed throughout the perykarya
of both non-transgenic (C, E) and mutant VAPB (D’, F’) motor neurons irrespective of the presence of VAPB inclusions, but G, H) Double labeling for
HA and the ribosomal proteins P0 (G) or phosphorylated-S6 (H) shows that mutant VAPB inclusions are P0 and phospho-S6-immunonegative but the
surrounding cytoplasm is always intensely P0 (arrows in G) and phospho S6-positive (H). Arrow and insert in H show that also dendritic VAPB
inclusions are surrounded by high levels of ribosomes. I-L) Double labeling of VAPB or HA, with antibodies against the cis-Golgi protein GM130 (I, J),
lysosomal protein LAMP1 (K), and the FFAT-motif protein ORP9 (L), shows that VAPB inclusions (arrows in K and L) are immunonegative for these
proteins. Note the presence of autofluorescent structures, representing lipofuscin (aging pigment) in the motor neuron shown in L, which is from a
70 week old VM1 mouse. Bar in A, 10 μm.
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larly clear in motor neuronal dendrites, which showed
areas of intense phospho-S6 staining. Analysis of a large
number of dendritic VAPB inclusions (> 100) indicatedthat in all occasions they were present within an area of
intense phospho-S6 staining (Figure 2H’).
Mutant VAPB did not codistribute with the Golgi ap-
paratus marker GM130, and the presence of inclusions
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morphology (Figure 2I, J). Also markers for lysosomes
(LAMP1, Figure 2K) and endosomes (EAA1, not shown)
did not codistribute with inclusions and showed unaltered
distributions in motor neurons with inclusions. Finally
we screened antibodies against a variety of FFAT-motif
containing proteins, representing a major class of VAPB
interacting proteins [6,37,38] to determine whether these
proteins accumulate in the mutant VAPB inclusions.
Antibodies against NIR2 and ORP9 produced consistent
labeling in motor neurons. However, ORP9 (Figure 2L)
nor NIR2 (data not shown) immunoreactivity was present
in the mutant VAPB inclusions, consistent with the obser-
vation that the P56S mutation disrupts the FFAT-motif
binding domain of VAPB [6].
VAPB inclusions ultrastructurally are characterized by
smooth ER-like profiles and electron dense material
Transmission electron microscopy of spinal motor neu-
rons of VAPB-P56S transgenic mice from the lines VM1,
VM3 and VM5 revealed the ultrastructural correlate of
the mutant VAPB inclusions: i.e. regions, 0.3 to 2 μm in
diameter, within the rough ER (RER) that contained
smooth ER-like tubular and vesicular profiles and electron
dense material (Figure 3). These abnormal regions were
contacted by surrounding rough ER profiles (Figure 3A-D).
In multiple occasions the rough ER was continuous with
tubular profiles in the inclusions (Figure 3C). The electron
dense material in the inclusions was at the cytoplasmic
side of the tubular profiles and usually showed small dif-
fuse clusters, 50–75 μm in diameter, of higher electron
density (Figure 3C, D). The rough ER surrounding the
regions with abnormal ER showed a normal appearance,
and no abnormalities were observed in other organelles.
Analysis of spinal interneurons, revealed the same ER
abnormalities, indicating this abnormality does not de-
pend on specific features of the ER in motor neurons
(not shown). Analysis of mutant VAPB transgenic mice
of different age indicated that the inclusions were the
same in old (70–90 weeks; Figure 3D) versus young
(4–15 weeks) mice.
Several findings indicate that the structures consisting
tubular smooth ER-like profiles and electron dense ma-
terial indeed represent the ultrastructural correlate of
inclusions identified light-microscopically: First, their size,
frequency, and exclusive distribution within regions of
rough ER are consistent with those of inclusions identi-
fied light-microscopically. Second, this ER abnormality
does not occur in motor neurons of transgenic mutant
VAPB mice of the VM2 line, which do not show light-
microscopic inclusions (Table 1). Third, post-embedding
immunogold electron microscopy with anti-HA anti-
body, showed that HA-labeling was strongly enriched
within these abnormal ER compartments (Figure 3E;78.40 ± 16.98 particles/μm2 [10 inclusions] versus 0.32 ±
0.14 gold particles/μm2 in the surrounding cytoplasm and
0.24 ± 0.08 particles/μm2 in non-transgenic motor neuron,
n = 10 cells).
Stacked ER cisterns in wt-hVAPB motor neurons
Motor neurons of wt-hVAPB mice did not show the ER
abnormalities observed in VAPB-P56S transgenic mice,
indicating that these inclusions are a specific consequence
of mutant VAPB (Table 1). Instead a subset of motor
neurons in wild-type VAPB transgenic mice, showed an-
other ER abnormality, i.e. stacked ER, consisting of flat
or circular arrays of parallel narrow cisterns (Figure 4A).
The cisterns were separated by a 17 ± 2 nm thick layer
(Figure 3A). These stacked ER resembled previously
reported stacked ER (also termed organized smooth ER
[OSER], or crystaloid ER) observed in cells expressing
high levels of certain ER membrane proteins [39,40] in-
cluding cells coexpressing VAPB together with FFAT-
motif protein [41,42]. Stacked ER was usually localized
in the rough ER, the superficial cisterns being continuous
with rough ER cisterns (Figure 4A). Occasionally, however,
stacked ER was found in other cellular compartments
such as near synapses (Figure 4B). Immunogold labeling
showed increased anti-HA immunoreactivity within stacks
(Figure 4C). Remarkably, in one line of wt-hVAPB mice
(line VW1) we noted a variant of stacked ER, where ER
cisterns were curved, the lumen of the cisternae was
expanded and the space linking cisterns together was
considerably more electron dense (Figure 4D). This elec-
tron dense form of stacked ER was continuous with both
‘regular’ ER stacks and rough ER profiles (inserts in
Figure 4D). Both the ‘regular’ and the electron-dense
irregular variant of stacked ER were never observed in
VAPB-P56S transgenic mice.
Gradual loss of mutant VAPB inclusions in axotomized
motor neurons
Together our confocal and electron microscopic data indi-
cate that inclusions in VAPB-P56S transgenic mice represent
unique ER associated structures. Analysis of the expres-
sion of two unfolded protein response target genes, i.e. the
ER chaperone Bip (Grp78, Hspa5) and Chop (Gadd153)
by immunofluorescence and qRT-PCR showed unaltered
expression in both wild-type and mutant VAPB transgenic
mice (Additional file 1: Figure S3), indicating that the ex-
pression of mutant VAPB per se or the presence of mutant
VAPB inclusions do not triggers induction of unfolded
protein response. Analysis of motor behavior by accelerat-
ing rotarod, hanging wire and hind limb extension tests in
a cohort of 46 mutant VAPB transgenic mice from differ-
ent lines including double transgenic mice generated by
intercrossing mice from VM1 and VM5, showed that the
far majority (44 of 46) of mice reached the age of 2 years
Figure 3 Mutant VAPB inclusions are localized in the RER and consist of smooth ER-like tubular profiles and electron dense material.
A-D) Transmission electron photomicrographs of mutant VAPB inclusions in spinal motor neurons of a 6 weeks old VM1 (A, B), a 6 week old VM3
(C), and a 70 weeks old VM1 x VM5 mouse (D). Note in A that the inclusions (red arrows) are localized within normal appearing rough ER (RER).
Other organelles such as Golgi apparatus (Go) and mitochondria (m) are unaltered (A, B). In C the ER lumen is accentuated in green to outline
the continuity of tubular smooth ER like profiles in the inclusions with the surrounding rough ER cisterns. Note in C and D that the electron
dense material in the inclusions has a patchy appearance (red arrows). E) Post-embedding immunogold electron microscopy with anti-HA
antibody showing that HA-labeling is preferentially associated with the electron dense material in the inclusions (see insert). The dashed lines
outline two distinct inclusions. Color overlay in A: red, area outside the motor neuron; yellow, nucleus; green, lumen of ER. Scale bars: 2 μm (A),
500 nm (B), 200 nm (C, D, E).
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Table 1 Summary of ER abnormalities in Thy1.2-hVAPB transgenic lines
Mouse line HA-staining ER abnormalities
Tubular ER Stacked ER Electron dense stacked ER
hVAPB-wt
VW1 +++++ - + +
VW2 ++++ - + -
VW3 ++++ - + -
hVAPB-P56S
VM1 ++ + - -
VM2 + - - -
VM3 ++ + - -
VM5 ++ + - -
VM1 + VM5 +++ + - -
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neuronal degeneration (Additional file 1: Figure S4; and
Table S1). These findings are consistent with data from
previous studies reporting normal survival and the ab-
sence of motor abnormalities in mutant VAPB transgenic
mice [17,18]. Remarkably, however, two (of 46) mice de-
veloped late onset progressive motor impairment, and
axonal degeneration in peripheral nerve (Additional file 1:
Figure S5; and Table S1). Although the number of these
two mice with a motor phenotype is too low to conclu-
sively link the phenotype to VAPB-P56S expression, the
mice shared two interesting features, i.e. the expression of
ATF3, a stress transcription factor that is expressed in
motor neurons following multiple pathological conditions
[43-45], in a large number of motor neurons (Figure 5A,
B). More importantly, double labeling with anti-HA anti-
body showed that none of the ATF3 expressing motor
neurons in the mice with a motor phenotype showed VAPB
inclusions (Figure 5C). These data suggest a correlation
between ATF3 expression, axonal degeneration and the
absence of VAPB inclusions in motor neurons of mutant
VAPB transgenic mice.
To further investigate the connection between ATF3
expression, axonal damage and the absence of VAPB in-
clusions, we examined the effect of axotomy on inclusions
in sciatic nerve motor neurons of VM1 mice. Axotomy
results in a strong induction of ATF3 expression in motor
neurons within 12 hours, which lasts for more than
5 weeks post transection [44,46]. Analysis of inclusions
in axotomized ATF3-positive motor neurons revealed a
gradual reduction of the size of inclusions starting within
24 hours post-axotomy (Figure 5D-G). Ultimately, axotomy
resulted in the total absence of inclusions and diffuse HA
labeling 2–3 weeks post-axotomy (Figure 5D-G). The dif-
fuse HA labeling in 2–3 weeks axotomized VM1 motor
neurons strongly resembled HA-labeling in motor neurons
of MP1 and MP2 mice described above. Importantly, the
level of HA-labeling in 2–3 weeks axotomized VM1 motorneurons is considerable higher than in VM2 motor neu-
rons, indicating that the absence of inclusions cannot sim-
ply be explained by reduced VAPB-P56S expression levels.
Together the data indicate that mutant VAPB inclusions in
motor neurons of VAPB-P56S transgenic mice are revers-
ible ER-associated structures.
VAPB inclusions are immunoreactive for proteins of the
ER associated degradation (ERAD) quality control pathway
Being a misfolded ER membrane protein, VAPB-P56S is
likely to be degraded by the ERAD-C pathway, i.e. ER as-
sociated degradation (ERAD) for ER substrates exposing a
misfolded domain into the cytoplasm [47,48]. This pathway
like other ERAD pathways involves polyubiquitination of
the substrate, followed by extraction from the ER mem-
brane for delivery to the proteasome. Studies in Drosophila
and mammalian cells have documented that P56S-VAPB
can be polyubiquitinated and that mutant VAPB inclusions
are immunostained with antibodies against ubiquitinated
epitopes [5,20,49], although in our hands VAPB-P56S in-
clusions in transfected HeLa cells were relatively weakly
positive for ubiquitinated epitopes as compared to inclu-
sion formed by mutant huntingtin [6]. However, using the
monoclonal antibody FK2 that immunoreacts with mono-
and polyubiquitinated epitopes, mutant VAPB inclusions
in our VAPB-P56S mice were strongly stained (Figure 6A).
Interestingly, motor neurons without inclusions in our
VAPB-P56S mice showed a diffuse increase of FK2-
immunostaining throughout the cytoplasm as compared
to motor neurons from non-transgenic mice. This was
observed in 2 independent experiments with spinal cord
sections from both VM1 and VM3 mice and their respect-
ive non-transgenic littermates (Figure 6B-D). These data
raise the possibility that also diffusely distributed mutant
VAPB which is not in the inclusions is ubiquitinated.
We next stained for Valosin-containing protein (VCP/
p97, cdc48 in yeast), which is an essential ERAD compo-
nent that provides mechanical force for extracting substrate
Figure 4 Stacked ER in motor neurons of wild-type VAPB overexpressing mice. A, B) Transmission electron photomicrographs showing
stacked ER in motor neurons from a 30 week old wild-type VAPB overexpressing mouse (line VW3). The ER cisterns in the stacks are thin, while
the cytosolic faces of the cisternal membranes are separated by a 17.2 ± 1.6 nm thick layers (A). In A“ the ER lumen is accentuated in green to
outline the continuity of lumen of stacked cisterns with the surrounding ER cisterns. B illustrates stacked ER next to a synapse. C) Post-embedding
anti-HA immunogold electron photomicrographs, showing that transgenic wild-type VAPB is concentrated in the stacked ER. D) Transmission
electron photomicrograph of a motor neuron of an 8 week old mouse from line VW1 showing stacked ER (black arrow) and a variant of stacked
ER (red arrows), consisting of curved more irregular ER cisterns, and electron dense intra-cisternal spaces (inserts in D). Color overlay: yellow,
nucleus (A); purple, presynaptic bouton (B); green, lumen of ER (A, B). Scale bars: 2 μm (D), 500 nm (B), 100 nm (A”, C).
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VCP-immunoreactivity was present in the nucleus and the
perikaryon, with higher staining intensities of the nucleus
(Figure 6I). Motor neurons with mutant VAPB inclusions
showed the same overall staining, but in addition showed
intense VCP staining within the inclusions, indicative of an
accumulation of VCP in the inclusions (Figure 6E). Staining
for Derlin-1, an ER membrane spanning protein that playsa role in ERAD of many substrates, including tail-anchored
proteins [50], showed that VAPB inclusions were also
immunoreactive for Derlin-1 (Figure 6F). However, un-
like VCP, Derlin-1 immunoreactivity was not specifically
enriched in the inclusions, showing the same overall dis-
tribution in non-transgenic motor neurons and motor
neurons with inclusions (compare Figure 6F’ and H). Fi-
nally, we stained for BAP31 an ER membrane chaperone
Figure 5 Gradual loss of mutant VAPB inclusions in axotomized motor neurons. A-C) Representative images (A) and bar graph (B) showing
ATF3 expression in a large number of motor neurons of two mutant VAPB mice that developed progressive motor abnormalities. The mice with
a motor phenotype consisted of a mouse from line VM3 (mouse MP1, onset 61 weeks) and line VM1xVM5 (mouse MP2, onset 74 weeks). Non-trangenic
(non-tg, n = 4) and transgenic littermates (n = 5) killed at the age of 104 weeks show ATF3 expression in a low proportion of motor neurons.
C) Confocal images of motor neurons double-labeled for HA and ATF3 showing the absence of VAPB inclusions in ATF3 expressing motor
neurons of mouse MP2. D-G) Gradual loss of mutant VAPB inclusions in axotomized motor neurons. D) Confocal image of lumbar motor neurons of
a VM1 mutant VAPB mouse, 7 days after sciatic nerve transection, showing that axotomized motor neurons identified by ATF3 expression
(ipsilateral) have no or very small VAPB inclusions as compared to control (contralateral) VM1 motor neurons. E) Representative images of
axotomized motor neurons (ipsilateral, ATF3 positive) from VM1 mice killed at different time points after axotomy. Note the gradual reduction of the
size of VAPB inclusion following post-axotomy, ultimately leading to diffuse perikaryal HA staining 2–3 weeks post-axotomy. F, G) Bar graphs showing
the inclusion size expressed as mean number of pixels per inclusion (F), and the percentage of HA-labeled motor neurons with inclusions (G). Values in F
represent means ± SE from more than 20 motor neurons from 2–3 mice. *, **, ***: P < 0.05, P < 0.01, P < 0.001 compared to contralateral (unpaired
Student’s t-test). Scale bars: 100 μm, (A), 25 μm (D), 10 μm (C, E).
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Figure 6 Mutant VAPB inclusions are ubiquitin-positive and enriched in ERAD components. A-C) Representative confocal images of the
distribution of ubiquitinated epitopes labeled with the FK2 antibody in motor neurons of mutant VAPB line VM1 with (A) or without (B) inclusions, and
non-transgenic littermates (C). Note high level of FK2-immunoreactivity in inclusions (A) and diffuse increase as compared to non-transgenic motor
neurons in VM1 motor neurons without inclusions (B). D) Bar graph of FK2-immunofluoresencesignal in non-transgenic versus VM1 and VM3 motor
neurons without inclusions. Values are means ± SE and are from lumbar L4 segments from 4 non-transgenic, 2 VM1 and 2 VM3 mice embedded in a
single gelatin block (see methods). E-I) Confocal image of mutant VAPB (line VM1, E-G) or non-transgenic (H, I) spinal motor neurons double-labeled
for VAPB or HA and ERAD components, i.e. VCP/p97 (E, I), derlin-1 (F, H), and BAP31 (G). Note, enrichment of VCP (E) and BAP31 (G) staining in the
mutant VAPB inclusions; derlin-1 although present does not show preferential enrichment is not selectively enriched in the mutant VAPB inclusions.
Scale bars: 10 μm (A, H), 25 μm (E).
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mutant VAPB inclusions in transfected HeLa cells [52].
Accordingly, we found a marked enrichment of BAP31
immunoreactivity in mutant VAPB inclusions in our
transgenic mice (Figure 6G). Together the data suggest
that mutant VAPB inclusions are a region of increased
ERAD activity.
VAPB inclusions may represent an ER associated
degradation (ERAD) quality control compartment
To further study the relationship between the ERAD
pathway and the mutant VAPB inclusion we moved to
primary neuron cultures. Like mutant VAPB inclusions
in transgenic mouse motor neurons, inclusions in hip-
pocampal neurons transfected with myc- or HA-tagged
VAPB-P56S were markedly enriched in ubiquitinated
epitopes, VCP, Derlin-1 and BAP31 (Figure 7A-E). Therecruitment of BAP31 to the mutant VAPB inclusions
was confirmed by coexpressing a RFP-tagged BAP31
(Figure 7F, G). To determine whether the recruitment of
ERAD factors to mutant VAPB inclusions depended on
the insertion of VAPB-P56S in the ER membrane, neu-
rons were transfected with GFP-tagged VAPB-P56S that
lacked the transmembrane domain required for insertion
in the ER membrane [52]. ΔTM-VAPB-P56S accumu-
lated in inclusions that usually were larger and showed
a more restricted distribution than VAPB-P56S inclusions
(Figure 7H, I). Importantly, ΔTM-VAPB-P56S inclusions
were not enriched in VCP and Derlin-1 (Figure 7H, I)
indicating that the recruitment of these ERAD factors
depended on the association of mutant VAPB with the
ER. In contrast, VAPB-P56S with the transmembrane
of another protein (i.e. CD8) accumulated in inclusions
that were enriched in VCP (Figure 7J). Furthermore,
Figure 7 Mutant VAPB inclusions in primary cultured hippocampal neurons are enriched in ERAD components. A-E) Maximal projections
of confocal stacks of primary cultured hippocampal neurons transfected with Myc-VAPB-P56S showing intense staining of ubiquitinated epitopes
(FK2, A), derlin-1 (B), VCP (C, D) and BAP31 (E) in mutant VAPB inclusions. F, G) Co-expression of Myc-VAPB-P56S and RFP-BAP31 shows that
mutant VAPB inclusions recruits a large portion of RFP-BAP31 (F), while in single RFP-BAP31 transfected neurons, RFP-BAP31 has a diffuse
distribution (G). H, I) Hippocampal neurons transfected with GFP-tagged VAPB-P56S lacking the transmembrane domain (ΔTM) develop inclusions
that are immunonegative for VCP (H) and Derlin-1 (I). J, K) Transfection of hippocampal neurons with VAPB-P56S-CD8TM with (K) or without
(J) myc-VAPB-P56S (green) shows that VAPB-P56S with the transmembrane domain of CD8 (immunostained with anti-CD8 antibody) accumulates in
the same inclusions as VAPB-P56S. Scale bar, 10 μm.
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P56S showed that VAPB-P56S-CD8TM accumulated in
the same inclusions as VAPB-P56S (Figure 7K) indicating
that the ER-membrane proteins with different trans-
membrane domains may accumulate in the same ERAD-
associated inclusions.
Inhibition of the ERAD pathway by inhibiting the
proteasome with MG-132 resulted in the formation of
larger inclusions (Figure 8A-D). Also shRNA-mediated
knockdown of BAP31 resulted in larger inclusions
(Figure 8C). Next we studied the effect of knockdown
of TEB4 (MARCH-VI), an ER membrane bound E3
ubiquitin ligase [53] that is the mammalian ortholog of
yeast Doa10, which is required for ubiquitination of
ERAD substrates with defective cytosolic domains [54].
ShRNA-mediated TEB4 knockdown resulted in a dra-
matic reduction in the size and number of mutant VAPBinclusions in VAPB-P56S expressing neurons (Figure 8E-G).
Together these data indicate that the sizes of the VAPB-
P56S inclusions strongly depend on ERAD activity.
VAPB-P56S inclusions differ from an ER protective
organelle (ERPO) associated with luminal ERAD substrates
The data indicate that VAPB-P56S inclusions in motor
neurons of our P56S-VAPB transgenic mice represent a
defensive cell response aimed at protecting cells from a
level of mutant ER protein that exceeds the capacity of
ER associated degradation. A recent study documented a
protective ER compartment termed ERPO (ER protective
organelle) in neurons of mice expressing mutated forms
of the ER membrane protein seipin that are associated
with an autosomal dominant motor neuron disease termed
seipinopathy [27,55]. The two seipinopathy mutations,
N88S and S90L, are located within an ER luminal loop
Figure 8 Altering ERAD influences the size of mutant VAPB inclusions. A-D) Incubation of GFP and Myc-VAPB-P56S transfected primary
cultured hippocampal neurons with MG132 to inhibit proteasome (B), or BAP31 shRNA construct to down regulate BAP31 expression (C) result in
increased size of mutant VAPB inclusions as compared to untreated cultures (A). The relative frequencies of small (< 50 pixels) and large (>200
pixels) were reduced and increased, respectively, by MG132 and BAP31 shRNA treatment (D). * and ***, P < 0.05 and <0.0001 compared to
control; one-way ANOVA, Tukey’s post-test. E-G) TEB4 shRNA reduces size and number of mutant VAPB inclusions in cultured hippocampal
neurons, also resulting in a reduction of the proportion of cytosol occupied by inclusions in TEB4-shRNA treated cells (G). *, P < 0.05 compared to
control (Student’s t-test). Scale bar, 10 μm.
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aggregation. Consistent with previous reports expression of
seipin-S90L and seipin-N88S in cultured neurons resulted
in small spherical inclusions with sizes in the same range as
VAPB inclusions. However, coexpression of seipin-N88S
or seipin-S90L with VAPB-P56S showed that the mutated
proteins accumulated in distinct inclusions (Figure 9). The
seipin inclusions were not immunostained with the FK2
antibody against ubiquitinated epitopes. Furthermore,
the seipin inclusions unlike the VAPB inclusions were
immunonegative for VCP, derlin-1 and BAP31. These data
show that VAPB inclusions are different from ERPO
formed by mutant seipin.
Discussion
Inclusions in motor neurons of transgenic VAPB-P56S
mice may represent an ER quality control compartment
In the present study we show that transgenic mice ex-
pressing an ALS8-linked mutant form of VAPB develop
a novel type of inclusion that is associated with the rough
ER and consists of smooth ER-like tubular profiles andelectron dense material. Several lines of evidence indicate
that this mutant VAPB inclusion represents an ER protein
quality control compartment: First, the presence of the
inclusions was not associated with signs of neuronal
malfunction or neuronal pathology. Second, the inclusions
are localized in the center of healthy appearing active
rough ER. Third, the inclusions are reversible as they
gradually disappear following axonal transection. Fourth,
the inclusions are enriched in factors that operate in the
ER associated degradation (ERAD) pathway, i.e. p97/VCP,
Derlin-1 and the ER membrane chaperone BAP31. And
fifth, inhibition of ERAD increased the size of the inclu-
sions. We propose that the inclusions in our mutant
VAPB transgenic mice represent an ER quality control
compartment that arises, when the amount of substrate
exceeds the capacity of ER associated degradation (ERAD).
This ERAD associated quality control compartment is
reminiscent of aggresomes that may form in condition of
excess of cytosolic aggregation-prone protein [4,56]. Com-
patible with this idea, mutant VAPB inclusions do not
occur in motor neurons of low-expressing mutant VAPB
Figure 9 Mutant VAPB inclusions do not colocalize with mutant seipin inclusions. Primary cultured hippocampal neurons cotransfected
with HA-VAPB-P56S and wild-type (A) S90L- (B), or N88L-mutant myc-tagged seipin constructs (C-F). Wild-type seipin shows a diffuse distribution
throughout the cell body (A), while seipin-S90L and seipin-N88S accumulate in small inclusions (B-E) resembling mutant VAPB inclusions.
However, seipin inclusions do not overlap with VAPB inclusions, and do not stain with antibody against ubiquitinated epitopes (FK2, C), VCP (D),
derlin-1 (E) and BAP31 (F). Scale bar, 10 μm.
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rons derived from induced pluripotent stem cells of ALS8
patients [57].
Several studies have reported on ER-derived inclusion-
like structures that are formed after expression of mutated
ER proteins in yeast or mammalian cells [55,58-60]. An
ER-derived structure termed ERPO (ER protective organ-
elle) has been identified as a protective ER compartment
in cells expressing the serpin α1-antitrypsin with an
E342K mutation, associated with liver disease in children
[58]. ERPO may represent an ER quality control pathway
for multiple ER substrates, since aggregation-prone mu-
tant forms of seipin that are associated with an autosomal
dominant motor neuron disease, accumulate in the same
compartment [27]. Our data show that mutant VAPB and
mutant seipin accumulate in different inclusions when
coexpressed, indicating that the mechanisms that operate
in the formation of VAPB inclusions differ from those
underlying the formation of ERPO. Other ER derived deg-
radation subcompartments include a quality control com-
partment for misfolded glycoproteins, termed ERQC [60]
and a compartment termed ERAC (ER associated compart-
ment) that is formed in yeast expressing a multispanning
membrane protein (Ste6p) with mutation in cytoplasmatic
domains [59]. ERAC comprises a network of tubulo-
vesicular structures that occasionally are continuous
with the ER profiles, and was found to prevent proteins
targeted for ERAD from entering the secretory pathway[59]. These properties are compatible with features of
VAPB inclusions. A hallmark of our VAPB inclusions is
their position in the center of normal appearing RER
that in motor neurons usually is organized in Nissl Bodies
[61] (Figure 2). This position indicates that mutant VAPB
is sorted in a direction opposite to the secretory pathway.
Further work is needed to determine whether mutant
VAPB inclusions represent an ERAC-like compartment,
and whether there are additional ER substrates with
misfolded cytosolic domains that accumulate in the same
structures. Our finding that mutant VAPB with a different
ER transmembrane domain accumulate in the same struc-
tures (Figure 7J, K) favors the notion that the mutant
VAPB inclusions represent a protective ‘waste basket’ for
multiple ERAD-C substrates.
The molecular mechanisms underlying the formation of
mutant VAPB inclusions remain to be further determined.
Previously, we have shown that their formation does not
require microtubule-dependent transport, which is instru-
mental for the formation of aggresomes and several other
quality control compartments [4,6]. Here, we show that
shRNA-mediated knock-down of the ER membrane bound
E3 ligase TEB4 (MARCH-VI) severely reduces the size
and number of mutant VAPB inclusions. TEB4 and its
yeast ortholog Doa10, mediate ubiquitination of mul-
tiple ERAD-C substrates [53,54], and accordingly TEB4
may mediate ubiquitination of mutant VAPB to target it
for the ERAD machinery [54,62-64]. These data suggest
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early step in the formation of VAPB inclusions. We also
found that knock-down of the ER membrane chaperone
BAP31 increases the size of VAPB inclusions. BAP31
has been implicated in ERAD [24,51], accumulates in
the mutant VAPB inclusions, and may be involved in
the interaction of ubiquitinated mutant VAPB with VCP.
In this scenario the absence of BAP31 would prevent effi-
cient extraction of mutant VAPB from the ER membrane
by VCP. Some proteins that interact with the transmem-
brane domain of mutant VAPB, e.g. wild-type VAPs [6]
and YIF1A [65], are recruited to the VAPB inclusions,
raising the question what happens with these proteins
during ERAD of mutant VAPB. Another question is how
the formation of ER quality control compartments such as
VAPB inclusions, are connected to unfolded protein re-
sponse pathways that may be activated in conditions of
proteotoxic ER stress and overload of ERAD, and that
have been implicated in ALS pathogenesis [66].
Wild-type VAPB overexpression causes stacked ER
Recent work of Borgese and co-workers [5,52] suggests
that VAPB-P56S inclusions in HeLa cells predominantly
consist of a special form of stacked ER, made of two
or three tightly apposed ER cisternae separated by an
electron-dense layer [5,52]. We did not observe this or
any other form of stacked ER in our mutant VAPB ex-
pressing lines. VAPB inclusions in HeLa cells are also
BAP31 [52] and VCP/p97-positive (data not shown), and
mutant VAPB was shown to be rapidly ubiquitinated, and
degraded in a proteasome and VCP/p97 dependent way [5],
suggesting that as in neurons mutant VAPB inclusions may
represent an ERAD-associated compartment. Renewed
ultrastructural analysis of our HeLa cells showed that in
cells with relatively few and small inclusions they re-
sembled the inclusions observed in mutant VAPB mice
(Additional file 1: Figure S6A, B), while in cells with
more and larger inclusions they showed more complex
morphologies (Additional file 1: Figure S6C-E). Interest-
ingly, we noted patches of apposed ER cisternae separated
by a thin layer of electron dense cytosol, resembling the
apposed ER cisternae reported by Borgese and coworkers.
However, so far in our HeLa cells we have not identified
the relatively large domains of bi- or trilaminar ER docu-
mented by Borgese et al. [5,52]. Hence, the precise rela-
tionship between our VAPB inclusions and the remodeled
stacked ER of Borgese et al. remains to be determined.
Stacked ER occurred in motor neurons of our wild-
type hVAPB transgenic mice, and is a well-documented
phenomenon in cells that coexpress wild-type VAPB and
FFAT-motif proteins, presumably resulting from hetero-
typic interaction between VAPB and FFAT-motif pro-
teins [41,42]. Hence, stacked ER in motor neurons of
wild-type VAPB overexpressing mice may result fromexcessive VAPB interacting with endogenous FFAT-motif
protein. Remarkably, in one line of wild-type VAPB
overexpressing mice we observed a variant of stacked
ER where the cytosolic space linking the cisterns was
considerably more electron dense. These data indicate
that stacked ER in some conditions is irreversible, which
contrasts with the notion that stacked ER is a relatively
harmless and reversible phenomenon [39,40].
How does mutant VAPB cause motor neuron disease?
Consistent with previous studies [17,18] our data show
that neuron-specific mutant VAPB transgenic mice
generally do not develop motor symptoms and signs of
motor neuron degeneration. This contrasts with the
pathological phenotypes observed in drosophila express-
ing mutant VAPB (DVAP-P58S or DVAP-T48I) that
develop loss of function-like phenotypes, and are sug-
gestive of a dominant-negative mode of action of mutant
VAPB [6,7,19,49,67]. The absence of a phenotype in
mice may be explained by efficient degradation and the
accumulation of mutant VAPB in a protective compart-
ment that prevents mutant VAPB from accumulating at
sites where it could engage in aberrant interactions such
as the ER Golgi intermediate compartment (ERGIC), or
the axon. The same mechanisms may explain the late
and variable onset of disease in man [8,68,69]. Interest-
ingly, two (out of 46) mice of our aging cohort devel-
oped a late onset motor axonopathy that is reminiscent
of mutant VAPB induced disease in man. Although their
number is too low to draw conclusions, a striking fea-
ture of these mice with motor axon pathology was the
absence of VAPB inclusions, indicative of a negative cor-
relation between the presence of inclusions and the de-
velopment of pathology. However, in view of our finding
that inclusions gradually disappear in axotomized motor
neurons, an alternative explanation is that the inclu-
sions in the mice with motor axon pathology have
disappeared secondarily to the axonal pathology. Fur-
ther work is needed to determine the role of protective
pathways like ERAD and the formation of inclusions in
preventing disease onset in mutant VAPB expressing
mice, as well as the factors that cause the disappearance
of VAPB inclusions after axotomy.
A recent study with Vapb−/− mice has indicated that
VAPB deficiency leads to mild, late onset defects in motor
performance, but does not cause neuromuscular junction
abnormalities and muscle denervation [9]. These data sug-
gest that loss of VAPB function by itself is not sufficient to
trigger an ALS-like disorder perhaps because of compen-
satory actions by VAPA [9] and point to alternative or
additional mechanisms for mutant VAPB toxicity, such as
a gained toxic activity, or a dominant-negative effect. It
would be interesting to cross VAPB-P56S transgenic mice
with Vapb−/− mice to examine the presence of synergistic
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the presence of mutant VAPB.
Conclusions
In conclusion, the central finding of the present study is
that inclusions formed by ALS8-mutant VAPB in motor
neurons in transgenic mice represent a protective ER com-
partment that isolates misfolded and aggregated VAPB from
the rest of the ER. The data suggest that motor neurons are
capable of coping with mutant VAPB levels that exceed the
capacity of the ERAD systems. Whether similar protective
ER derived compartments occur in physiological and patho-
logical conditions in human central nervous system could
be analyzed by immunohistological approaches with anti-
bodies against BAP31 and VCP/p97.
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